(MENAFN- InvestorIdea)
Carneys Point NJ - July 15 2015 (www.investorideas.com newswire) CannaPharmaRx (OTCQB: CPMD) a leader in the research development and commercialization of cannabinoid-based drug products will be speaking and exhibiting at the Money Show in San Francisco CA. The Money Show will be held at the San Francisco Marriott Marquis from July 16 to July 18. CannaPharmaRx will be exhibiting at Booth #512.
Mr. Mathew Sherwood VP of Product Devlopment at CannaPharmaRx will be speaking in two workshops at the event:
On Saturday July 18 from 9:00am to 9:45am Mr. Sherwood alongside Mr. Staffan Hillberg of Heliospectra Mr. Scott Greiper of Viridian Capital Advisors and Mr. Matt McCall of Penn Financial Group will be discussing the opportunities and challenges of investing in publicly traded cannabis stocks. Click here for more information on the first session.
On Saturday July 18 from 12:00pm to 4:00pm Mr. Sherwood will be discussing investments in biotech businesses around the cannabis industry during The Cannabis Investing Symposium. Click here for more information on the second session.
The Money Show is the top finance and investor conference in the nation. Featuring renowned experts such as Mr. Steve Forbes editor-in-chief of Forbes magazine the Money Show serves as a premier platform for acquiring advice information and perspective on the challenging and ever-changing global investment landscape.
Click the picture below for more information on the Money Show San Francisco.
About CannaPharmaRx Inc.
CannaPharmaRx Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that once ingested are active in humans and animals through the 'endocannabinoid system' – one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies including: neurological disorders oncology infectious disease pain management inflammatory disease gastrointestinal disorders and ophthalmology. For more information please visit www.CannaPharmaRx.com.
Contact
Investor Relations:Michael Swartz Senior AnalystViridian Capital Advisors LLC212-333-0257mswartz@viridianca.com
Bridamary RosarioCannaPharmaRx Inc.856-376-0500bbrosario@cannapharmarx.com
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.